TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04371471

Intervention type: DIAGNOSTIC_TEST
Intervention: STC-19 score
Description: Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
Study: NCT05669287

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: CT Perfusion
Study: NCT02039297

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation
Description: Computer aided checklist and rounding tool implemented in the Intensive care unit environment
Study: NCT02832219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Molecular hydrogen

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04178096

Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement Intervention
Description: The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
Study: NCT01448447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammosite ML
Description: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
Study: NCT03031522

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-IRS
Description: According to experiment, 18F-IRS was non-toxic and stable in serum.
Study: NCT01448447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mammosite ML
Description: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
Study: NCT01812421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Health Education Protocol (HHEP)
Study: NCT03588390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Low strength tablet
Study: NCT02413164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A multimodal physiotherapy programme
Description: Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times.
Study: NCT02159742

Intervention type: OTHER
Intervention: Data Collection
Study: NCT01972958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive care
Description: comprehensice assessment,physical activity training, community resources referral, health education.
Study: NCT00825266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bosentan
Description: Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
Study: NCT01831622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
Study: NCT01502787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study: NCT01831622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
Study: NCT02215122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGR001
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair® Diskus®
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study: NCT03588390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Low strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Low strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Middle strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Middle strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Middle strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: High strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: High strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to low strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to low strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to low strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to middle strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to middle strength tablet
Study: NCT02215122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide™ Accuhaler™
Description: Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
Study: NCT04364373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left colon resection
Description: This procedure is performed for tumours in splenic flexure and proximal and descending colon.~Left colic artery is divided at its origin. Sigmoid arteries and superior rectal arteries are preserved. Inferior mesenteric vein is divided at the lower border of the pancreas. The colon is divided about 10 cm proximal and distal to the tumour. Mesocolic fascia is preserved and the length of the vessel trunk of the mesocolon corresponds to the level of lymph node dissection. After removal of the resected colonic segment a handsewn or stapler end-to-end or side-to-side colonic anastomosis is performed.
Study: NCT01502787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study: NCT02669784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Contrast (Omnipaque) 40mL
Description: The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Contrast (Omnipaque) 50 mL
Description: The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Study: NCT03083587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal lifestyle
Description: Normal lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Mild exercise 3 min every half hour

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle and fat biopsy
Description: Biopsy under local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle and fat biopsy
Description: Biopsy under local anesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Glucose concentrations during the study period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring
Description: Glucose concentrations during the study period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitoring (ActivePal)
Description: Objective measurements of standing and sitting time

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring (ActivePal)
Description: Objective measurements of standing and sitting time
Study: NCT04791982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational sessions
Description: Firstly, the literature was scanned and a education booklet prepared after the opinions of 5 academic nurses, who are experts in the field of oncology, was used. The booklet was included colorectal cancer treatment, symptoms that may develop due to chemotherapy and information on their control, psychosocial support of caregiving family members. Interviews and educational sessions with family members who agreed to participate in the study were held in one-on-one and face-to-face meeting room. These interviews lasted approximately 45 to 60 minutes for each family member. In the interviews, a educational booklet containing information on nutrition, exercise, symptom management, physical aspects of care and disease-specific care was used to present information to caregivers. All of educational sessions were performed by the single researcher.
Study: NCT00895401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro with Carb Steady
Description: Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for malnourished maintenance hemodialysis patients
Study: NCT04014764

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
Study: NCT04216810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle strengthening exercises
Description: segmental stabilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle strengthening exercises and dry cupping
Description: segmental stabilization exercises and dry cupping
Study: NCT04447170

Intervention type: PROCEDURE
Intervention: Simple repair or Graham technique
Description: Simple suture with or without omental protective patch
Study: NCT02747238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound
Description: Palpation of anatomical landmarks is used for placement of labor analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion
Description: An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural infusion
Description: An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
Study: NCT02471651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant (0.7 mg)
Description: Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal anti-VEGF injection
Description: This injection may be ranibizumab, bevacizumab, or aflibercept.
Study: NCT05019248

Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).

Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).

Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).

Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).

Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
Study: NCT02616874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv vaccine
Description: Dose: 2x10e8 pfu, Interval: weeks 0 and 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
Study: NCT02251327

Intervention type: DEVICE
Intervention: Investigational Xpert DST test
Description: One investigational test performed directly on the same sputum specimen.

Intervention type: DEVICE
Intervention: Investigational Xpert DST test
Description: One investigational test performed directly on the same sputum specimen.
Study: NCT04824482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted treadmill gait training (RTGT)
Description: Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-assisted treadmill gait training (TTGT)
Description: Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
Study: NCT04419948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Butter 39 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Butter 39 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined olive oil
Description: Refined olive oil (40 ml).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO with 250 mg/kg oleocanthal
Description: Extra virgin olive oil containing 250 mg/kg oleocanthal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO with 500 mg/kg oleocanthal
Description: Extra virgin olive oil containing 500 mg/kg oleocanthal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg
Study: NCT02285439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
Study: NCT04072510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-esteem group
Description: The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
Study: NCT04477928

Intervention type: DIAGNOSTIC_TEST
Intervention: Sera and whole blood sampling
Description: * Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential Gene Expression (DGE)
Description: Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
Study: NCT02055131

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Study: NCT04437940

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal fluid Covid-19 PCR test
Description: Vaginal fluid samples are tested for Covid-19
Study: NCT04405518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
Study: NCT03407794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented vegetable
Description: The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fermented vegetable
Description: The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks